The Relevance of Content Marketing In Pharma

“Nearly half of pharma industry may come under price control” – was the headline of a media report of June 7, 2017. Although, National Pharmaceutical Pricing Authority (NPPA) has apparently denied any such move, the fact is that the number … Continue reading

Price Negotiation For Patented Drugs: Still Continues A Policy Paralysis

Many poor and even middle-income patients, who spend their entire life savings for treatment of life-threatening ailments, such as, cancer, have been virtually priced out of the access to patented new drugs, across the world. As articulated by the American … Continue reading

Drugs & Devices: Chasing Never-Enough Profit And Price Control

On July 20, 2016, the Union Ministry of Health of India announced the addition of Coronary Stents to the National List of Essential Medicines (NLEM) 2015 with immediate effect, bringing them under the Drug Price Control Order. Reacting sharply to … Continue reading

Patented Drugs: A Dangerous Pricing Trend Impacting Patient Access

The upcoming trend of jaw dropping high prices for new patented drugs sends a ‘storm signal’ to many stakeholders, especially for its adverse impact on patient access. Even more intriguing, such high and insane prices are being fixed rather arbitrarily, … Continue reading

The Next Frontier: Frugal Innovation For High-Tech Drugs

Should drug innovation models remain as expensive as what these are claimed to be now by the global pharma industry, in general? Finding a credible, appropriately quantifiable, and generally acceptable answer to this question is critical. It won’t, then, just … Continue reading

Arbitrary Pricing of Essential Drugs Invites State Intervention

Arbitrary drug pricing has now become a subject of a raging debate, all over the globe. It involves both patented and generic drugs, as we have recently witnessed in the largest pharma market in the world – the United States. … Continue reading

Drug Price Control in India: A Fresh Advocacy With Blunt Edges

It is no-brainer that the advocacy initiatives to influence the new Government doing away with the ‘Drug Price Control’ in India has re-started by flooring the gas pedal. A fresh invigorating effort, apparently a pretty expensive one, has been initiated … Continue reading

India’s Drug Pricing Policy: “Absurd, Unreasonable And Irrational” – Supreme Court

On July 15, 2015, while hearing a petition related to the current ‘Market Based Drug-Pricing Policy’ of the country, the Supreme Court of India expressed its bewilderment on the very rationality of the ‘National Pharmaceutical Pricing Policy 2012’ and directed the … Continue reading